NCT06251492View on ClinicalTrials.gov

Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

December 30, 2025

Conditions
Prostate Cancer MetastaticCastration-resistant Prostate Cancer
Interventions
RADIATION

Stereotactic body radiotherapy

8 Gray x 3 for 2 cycles

DRUG

Adebrelimab

Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression

Trial Locations (3)

200000

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

361000

RECRUITING

Fudan University Shanghai Cancer Center Xiamen Branch., Xiamen

All Listed Sponsors
lead

Fudan University

OTHER